As it happened: A bidding war for an antibiotic maker in a market that has ravaged its peers

As it happened: A bidding war for an antibiotic maker in a market that has ravaged its peers

Source: 
Endpoints
snippet: 

In a bewildering twist to the long-suffering market for antibiotics — there has actually been a bidding war for an antibiotic company: Tetraphase.

It all started back in March, when the maker of Xerava (an FDA approved therapy for complicated intra-abdominal infections) said it had received an offer from AcelRx for an all-stock deal valued at $14.4 million.